Madrigal Pharmaceuticals announces positive outcome from pre-planned DSMB safety review
Madrigal announced the Company’s independent DSMB recommended that both studies continue without protocol modifications. Madrigal also announced the Phase 2 study of MGL-3196 for treatment of HeFH has enrolled 113 patients , exceeding the target patient enrollment of 105 patients. September 19, 2017